Effects of DC on an Innovative Animal Model of Cardiometabolic Syndrome.
Gustavo Ratti da Silva, Arianne Jung Kluck, Edilson Rodrigues Albuquerque, Lucas Pires Guarnier, Fernanda de Abreu Braga, Ester Pelegrini Silva, Karina Sposito Negrini, Juliana Aparecida Mendon��a, Zilda Cristiani Gazim, Arquimedes Gasparotto Junior, Jo��o Tadeu Ribeiro-Paes, Francislaine Aparecida Dos Reis L��vero
Author Information
Gustavo Ratti da Silva: Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Animal Science with Emphasis on Bioactive Products, Paranaense University, Umuarama 81531-980, Brazil. ORCID
Arianne Jung Kluck: Laboratory of Cardiometabolic Pharmacology, Federal University of Paran�� (UFPR), Curitiba 81531-990, Brazil. ORCID
Edilson Rodrigues Albuquerque: Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Animal Science with Emphasis on Bioactive Products, Paranaense University, Umuarama 81531-980, Brazil. ORCID
Lucas Pires Guarnier: Department of Genetic, Ribeir��o Preto Medical School, University of S��o Paulo, Ribeir��o Preto 14049-900, Brazil. ORCID
Fernanda de Abreu Braga: Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama 81531-980, Brazil.
Ester Pelegrini Silva: Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama 81531-980, Brazil.
Karina Sposito Negrini: Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama 81531-980, Brazil.
Juliana Aparecida Mendon��a: Chemistry Laboratory of Natural Products, Post-Graduate Program in Biotechnology Applied to Agriculture, Paranaense University, Umuarama 81531-980, Brazil. ORCID
Zilda Cristiani Gazim: Chemistry Laboratory of Natural Products, Post-Graduate Programs in Animal Science and Biotechnology Applied to Agriculture, Paranaense University, Umuarama 81531-980, Brazil. ORCID
Arquimedes Gasparotto Junior: Laboratory of Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados 79804-970, Brazil. ORCID
Jo��o Tadeu Ribeiro-Paes: Laboratory of Genetics and Cell Therapy (GenTe Cel), Department of Biotechnology, S��o Paulo State University, Assis 19806-900, Brazil.
Francislaine Aparecida Dos Reis L��vero: Laboratory of Cardiometabolic Pharmacology, Federal University of Paran�� (UFPR), Curitiba 81531-990, Brazil. ORCID
Cardiometabolic syndrome (CMS) is a complex clinical condition that encompasses metabolic dysregulation, cardiovascular disease, and diabetes risk factors. Worldwide, CMS is underdiagnosed, and its occurrence significantly increases cardiovascular morbimortality. Despite available pharmacological treatments, the approach is fragmented, and the associated clinical conditions are treated independently. This approach may be partially due to limited preclinical models to mimic the clinical conditions of CMS. Therefore, our study aims to present an innovative animal model of cardiometabolic syndrome and evaluate the effects of on the set of clinical alterations associated with the condition. Female Wistar rats were induced to develop diabetes, fed a cholesterol-enriched diet, and exposed to the smoke of 9 cigarettes/day for 6 weeks. During the last 2 weeks, the rats were treated with vehicle, (30, 100, and 300 mg/kg), or a combination of simvastatin and insulin. At the end of the treatment, plasma lipid levels were measured, and the liver was analyzed histologically for hepatic lipid quantification and oxidative stress assessment. Phytochemical analysis revealed seven phenolic acids and six flavonoids in the extract. showed significant hepatoprotective effects, reducing AST and ALT levels and lowering both plasma and hepatic lipid levels. The extract also reversed hepatic steatosis and demonstrated antioxidant properties. These findings suggest that may be a therapeutic option for the metabolic dysregulation present in CMS.
